476 related articles for article (PubMed ID: 33956075)
1. Visual Acuity, Vitreous Hemorrhage, and Other Ocular Outcomes After Vitrectomy vs Aflibercept for Vitreous Hemorrhage Due to Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Beaulieu WT; Maguire MG; Antoszyk AN; Chow CC; Elman MJ; Jampol LM; Salehi-Had H; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):725-733. PubMed ID: 33956075
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intravitreous Aflibercept vs Vitrectomy With Panretinal Photocoagulation on Visual Acuity in Patients With Vitreous Hemorrhage From Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Antoszyk AN; Glassman AR; Beaulieu WT; Jampol LM; Jhaveri CD; Punjabi OS; Salehi-Had H; Wells JA; Maguire MG; Stockdale CR; Martin DF; Sun JK;
JAMA; 2020 Dec; 324(23):2383-2395. PubMed ID: 33320223
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy.
Diabetic Retinopathy Clinical Research Network*
JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
Glassman AR; Baker CW; Beaulieu WT; Bressler NM; Punjabi OS; Stockdale CR; Wykoff CC; Jampol LM; Sun JK;
JAMA Ophthalmol; 2020 Apr; 138(4):341-349. PubMed ID: 32077907
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
Abd Elhamid AH; Mohamed AAEA; Khattab AM
BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
[TBL] [Abstract][Full Text] [Related]
6. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
Martinez-Zapata MJ; Salvador I; MartĂ-Carvajal AJ; Pijoan JI; Cordero JA; Ponomarev D; Kernohan A; SolĂ I; Virgili G
Cochrane Database Syst Rev; 2023 Mar; 3(3):CD008721. PubMed ID: 36939655
[TBL] [Abstract][Full Text] [Related]
7. Changes in activity impairment and work productivity after treatment for vitreous hemorrhage due to proliferative diabetic retinopathy: Secondary outcomes from a randomized controlled trial (DRCR Retina Network Protocol AB).
Beaulieu WT; Maguire MG; Antoszyk AN;
PLoS One; 2023; 18(11):e0293543. PubMed ID: 37972038
[TBL] [Abstract][Full Text] [Related]
8. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
[TBL] [Abstract][Full Text] [Related]
9. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
10. Effect of Intravitreous Anti-Vascular Endothelial Growth Factor vs Sham Treatment for Prevention of Vision-Threatening Complications of Diabetic Retinopathy: The Protocol W Randomized Clinical Trial.
Maturi RK; Glassman AR; Josic K; Antoszyk AN; Blodi BA; Jampol LM; Marcus DM; Martin DF; Melia M; Salehi-Had H; Stockdale CR; Punjabi OS; Sun JK;
JAMA Ophthalmol; 2021 Jul; 139(7):701-712. PubMed ID: 33784735
[TBL] [Abstract][Full Text] [Related]
11. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
13. Five-Year Cost-effectiveness of Intravitreous Ranibizumab Therapy vs Panretinal Photocoagulation for Treating Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
Hutton DW; Stein JD; Glassman AR; Bressler NM; Jampol LM; Sun JK;
JAMA Ophthalmol; 2019 Dec; 137(12):1424-1432. PubMed ID: 31647496
[TBL] [Abstract][Full Text] [Related]
14. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
15. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
[TBL] [Abstract][Full Text] [Related]
16. Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy.
Maturi RK; Glassman AR; Josic K; Baker CW; Gerstenblith AT; Jampol LM; Meleth A; Martin DF; Melia M; Punjabi OS; Rofagha S; Salehi-Had H; Stockdale CR; Sun JK;
JAMA; 2023 Feb; 329(5):376-385. PubMed ID: 36749332
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM; Wykoff CC; Boyer D; Heier JS; Clark WL; Emanuelli A; Higgins PM; Singer M; Weinreich DM; Yancopoulos GD; Berliner AJ; Chu K; Reed K; Cheng Y; Vitti R
JAMA Ophthalmol; 2021 Sep; 139(9):946-955. PubMed ID: 34351414
[TBL] [Abstract][Full Text] [Related]
18. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial.
Halim S; Nugawela M; Chakravarthy U; Peto T; Madhusudhan S; Lenfestey P; Hamill B; Zheng Y; Parry D; Nicholson L; Greenwood J; Sivaprasad S
JAMA Ophthalmol; 2021 May; 139(5):501-507. PubMed ID: 33704351
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Visual Acuity and Central Subfield Thickness Changes When Treating Diabetic Macular Edema With Anti-Vascular Endothelial Growth Factor Therapy: An Exploratory Analysis of the Protocol T Randomized Clinical Trial.
Bressler SB; Odia I; Maguire MG; Dhoot DS; Glassman AR; Jampol LM; Marcus DM; Solomon SD; Sun JK;
JAMA Ophthalmol; 2019 Apr; 137(4):382-389. PubMed ID: 30676635
[TBL] [Abstract][Full Text] [Related]
20. Complications, Compliance, and 3-Year Outcomes After Endolaserless Vitrectomy With Aflibercept Monotherapy for Proliferative Diabetic Retinopathy-Related Vitreous Hemorrhage.
Kasetty VM; Starnes DC; Sood N; Qin LG; Moses MM; Frazier HK; Singh H; Marcus DM
Ophthalmic Surg Lasers Imaging Retina; 2023 Feb; 54(2):89-96. PubMed ID: 36780633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]